A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma.
暂无分享,去创建一个
A. Rossi | M. Federico | M. Fiegl | L. Marcheselli | C. Visco | A. Rambaldi | M. Mian | F. Zaja | S. Cortelazzo | A. Chiappella | S. Luminari | P. Mondello | S. Volpetti | A. Billio | A. Rambaldi
[1] S. Hawthorne. hospital , 2016, The Medical journal of Australia.
[2] I. Tannock,et al. Cognitive function and fatigue after diagnosis of colorectal cancer. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] M. Fiegl,et al. A success story: how a single targeted-therapy molecule impacted on treatment and outcome of diffuse large B-cell lymphoma. , 2014, Anticancer research.
[4] R. Gascoyne,et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. , 2014, Blood.
[5] A. Rosenwald,et al. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). , 2012, The Lancet. Oncology.
[6] A. López-Guillermo,et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. , 2011, The Lancet. Oncology.
[7] E. Giné,et al. Clinico-biological characterization and outcome of primary nodal and extranodal diffuse large B-cell lymphoma in the rituximab era , 2010, Leukemia & lymphoma.
[8] Dirk Hasenclever,et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] E. Jaffe,et al. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. , 2009, Hematology. American Society of Hematology. Education Program.
[10] L. Rimsza,et al. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] R. Gascoyne,et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. , 2007, Blood.
[12] Sigrid Stroobants,et al. Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Patrick Royston,et al. Explained Variation for Survival Models , 2006 .
[14] E. Jaffe. Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues , 2003 .
[15] P. Vyas,et al. Pathology and genetics: Tumours of haematopoietic and lymphoid tissues , 2001 .
[16] R. Fisher,et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. , 1998, The New England journal of medicine.
[17] Emili Montserrat,et al. A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[18] T M Grogan,et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[19] Horton,et al. Annals of Oncology , 1991, Springer US.
[20] F. Harrell,et al. Evaluating the yield of medical tests. , 1982, JAMA.